OpGen, Inc. news

• 208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial
• Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5%
• Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate antibiotic therapy in hospitalized patients with pneumoni

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, 

• Extended existing master services agreement with Sandoz, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
• Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics
• Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and